HealthPharma & Biotech
Nanobiotix SA

Nanobiotix boss upbeat as cancer technology passes latest test

Laurent Levy, Nanobiotix’s (EPA:NANO) chief executive, expects newsflow will continue strongly following the good results of a combined safety and dosing trial of its lead product in head and neck cancer patients.
The treatment, which boosts the effectiveness of radiotherapy by combining it with nanotechnology, was well-tolerated with no signs of leakage said Levy, with evidence as well of tumour shrinkage in most patients.
A number of clinical trial options in the head and neck cancer arena are now being assessed both in Europe and the US, Levy said.
In addition more results from application of its nanotechnology in soft tissue sarcoma and liver cancer are due later this year.

Quick facts: Nanobiotix SA

Price: £0.12

Market: EPA
Market Cap: £32.92 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Full interview: CB2 Insights licenses electronic data capture software to UK...

CB2 Insights (CSE:CBII-OTCQB: CBIIF) CEO Prad Sekar joined Steve Darling from Proactive Vancouver to discuss the company doing a deal with MYACCESS Clinics. This will allow CB2’s software to capture comprehensive data sets related to patient health and treatment histories and manage ongoing...

2 days, 10 hours ago

2 min read